CAR T and CAR NK cells in multiple myeloma: Expanding the targets

Multiple myeloma (MM) is a haematologic malignancy with significant improvements in the overall survival over the last decade. However, patients still relapse and die due to a lack of treatment options. Ultimately, novel therapies with the potential for long term remissions are needed for patients w...

Full description

Saved in:

Bibliographic Details
Published in:	Best practice & research. Clinical haematology 2020-03, Vol.33 (1), p.101141-101141, Article 101141
Main Authors:	Shah, Urvi A., Mailankody, Sham
Format:	Article
Language:	eng
Subjects:	Adoptive immunotherapy Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-Cell maturation antigen B-Cell Maturation Antigen - genetics B-Cell Maturation Antigen - immunology CAR T-cell therapy Cell Engineering - methods Chimeric antigen receptors Combined Modality Therapy - methods Gene Expression Humans Immunotherapy, Adoptive - methods Killer Cells, Natural - immunology Killer Cells, Natural - pathology Killer Cells, Natural - transplantation Molecular Targeted Therapy - methods Multiple myeloma Multiple Myeloma - genetics Multiple Myeloma - immunology Multiple Myeloma - pathology Multiple Myeloma - therapy Neoplasm Recurrence, Local Receptors, Chimeric Antigen - genetics Receptors, Chimeric Antigen - immunology T-Lymphocytes - immunology T-Lymphocytes - pathology T-Lymphocytes - transplantation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Multiple myeloma (MM) is a haematologic malignancy with significant improvements in the overall survival over the last decade. However, patients still relapse and die due to a lack of treatment options. Ultimately, novel therapies with the potential for long term remissions are needed for patients with advanced MM. Research efforts for such immune therapies were not successful until recently when the first immunotherapies for MM were approved in 2015 and many more are under development. In this review, we focus on adoptive cell therapies including CAR T-cell and CAR NK-cell therapies for patients with MM. We will provide an update on clinical and translational advances with a focus on results from ongoing clinical trials with BCMA targeted cellular therapies and the development of other novel targets, changes in the manufacturing process, trials focusing on earlier lines of therapy and combinations with other therapies as well as off the shelf products.
ISSN:	1521-6926 1532-1924